5 Stunning Pharma Stocks: GlaxoSmithKline plc, AstraZeneca plc, Shire PLC, BTG plc & Hikma Pharmaceuticals Plc

These 5 pharma stocks could be worth buying right now: GlaxoSmithKline plc (LON:GSK), AstraZeneca plc (LON:AZN), Shire PLC (LON:SHP), BTG plc (LON:BTG) and Hikma Pharmaceuticals Plc (LON:HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

Investor sentiment in GlaxoSmithKline (LSE: GSK) has stabilised in recent months, with shares in the company beating the FTSE 100‘s performance by 2% over the last three months. Certainly, challenges regarding top line growth remain, with the company struggling to match the loss of patents on blockbuster drugs that are now facing generic competition.

However, with it having an excellent pipeline of drugs, GlaxoSmithKline continues to offer superb long-term potential. And, with a dividend yield of 5.8%, a price to earnings (P/E) ratio of 15.3, and appealing defensive qualities, it could prove to be a sound buy for 2015.

AstraZeneca

While a bid from a US peer looks less likely now that the ‘tax inversion’ loophole is in the process of being closed, AstraZeneca (LSE: AZN) is still likely to be of interest to major pharmaceutical companies. That’s because under its new management team it has restructured, substantially beefed up its pipeline, and is delivering better profitability than previously forecast as a result.

As such, investor sentiment remains relatively strong even though AstraZeneca’s bottom line is still falling due to the effects of generic competition. However, with the financial firepower to engage in further acquisition activity, it would be of little surprise for positive growth to return and for the effect of this to be an increase in sentiment (and the share price) of AstraZeneca over the medium term.

Shire

Another pharma stock that was the subject of M&A activity last year was Shire (LSE: SHP). However, its potential suitor, AbbVie, pulled out after deciding that without the tax advantages it was not such a worthy proposition.

However, Shire remains a company with huge potential. For example, it is expecting to double sales between now and 2020 and, if met, this could push its share price substantially higher. And, looking a little nearer term, its bottom line growth forecasts of 9% for this year and 12% for next year highlight that it remains a relatively attractive pharma play at a time when many of its peers are struggling to deliver meaningful profitability growth.

BTG

Of course, when it comes to profit growth, sector peer BTG (LSE: BTG) is very tough to beat. Certainly, it may trade on an exceptionally high P/E ratio of 52.5 but, with its earnings forecast to rise by a whopping 38% in the next financial year, followed by 53% the year after that, it’s clear to see why investors are willing to pay such a premium for a slice of the company.

In fact, when BTG’s P/E ratio and growth forecasts are combined, they equate to a price to earnings growth (PEG) ratio of just 0.5. This indicates that growth is on offer at a very reasonable price and, as a result, BTG could prove to be a top performer this year.

Hikma

Despite having risen by a whopping 77% over the last year, shares in Hikma (LSE: HIK) could perform well in 2015. That’s because, as well as enjoying strong investor sentiment, the company still appears to be reasonably priced. For example, it has a PEG ratio of just 1.4 and, for a stock that has seen profits rise threefold in the last three years, this seems to be highly appealing.

Furthermore, with there being vast long term potential in the generic injectables space (in which Hikma has a firm foothold and is seeking to expand), its performance beyond the current year could prove to be impressive, too. As a result, Hikma could be a stock worth buying at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK has recommended BTG and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »